Yelena Y. Janjigian, MD
Gastrointestinal Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Gastrointestinal Malignancies
- New Chemotherapies
- Esophageal and Gastric Cancers
Request an Appointment
About Me
- Chief, Gastrointestinal Oncology Service
I am a medical oncologist who cares for people with cancers of the gastrointestinal (GI) tract. My clinical practice and research are focused on improving outcomes for people with esophageal and stomach cancers.
When patients first meet with me, they are often scared and have many questions. They usually want to know about their treatment options, chances for survival, and how their quality of life will be affected. I take the time to answer their questions clearly and honestly. My goal is to work with them to create the best possible care plan for their specific needs and preferences. I want my patients to leave our consultation feeling confident that they are in good hands.
As Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), I lead a dedicated team of experienced and compassionate physicians. My mission is to encourage research and the development of new therapies to help patients worldwide.
A gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Gastrointestinal Malignancies
- New Chemotherapies
- Esophageal and Gastric Cancers
Education
- MD, New York University School of Medicine
Residencies
- Internal Medicine - New York University School of Medicine/Bellevue Hospital
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Janjigian sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Janjigian
- A Phase 2 Study of AgenT-797 Plus Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancers
- A Phase 2 Study of AZD0901 Alone and With Anti-Cancer Drugs in People With Solid Tumors That Make Claudin 18.2
- A Phase 2 Study of Pembrolizumab Immunotherapy With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
- A Phase 3 Study of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in People with Previously Untreated Inoperable or Metastatic Stomach, Gastroesophageal Junction, or Esophageal Cancer
Read more
- A Phase I Study of TST001 in People with Locally Advanced or Metastatic Digestive Cancers
- A Phase IB/II Study of Trastuzumab Deruxtecan in People with Advanced Gastric Cancer or Gastroesophageal Junction Cancer
- A Phase II Study of Domvanalimab and Zimberelimab Immunotherapy with or without FOLFOX Chemotherapy in People with Esophageal, Gastroesophageal Junction, or Stomach Cancer
- Clinical Trials Co-Investigated by Dr. Janjigian
- A Phase 1 Study of BI 3706674 in People With Gastric and Esophageal Cancers
- A Phase 1 Study of EO-3021 in People With Advanced Esophagogastric Cancers
- A Phase 1 Study of HRO761 for People With Advanced Solid Tumors
- A Phase 3 Study of Bemarituzumab plus Chemotherapy and Nivolumab Immunotherapy in People with Stomach or Gastroesophageal Junction Cancer
- A Phase II Study of Amivantamab in People with Esophagogastric Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. PMID: 34912120; PMCID: PMC8959470.
Read more
Visit PubMed for a full listing of Dr. Janjigian’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Yelena Y. Janjigian discloses the following relationships and financial interests:
-
American Association for Cancer Research
Professional Services and Activities (Uncompensated) -
American Society of Clinical Oncology (ASCO)
Professional Services and Activities -
Arcus Biosciences, Inc.
Professional Services and Activities (Uncompensated) -
AskGene Pharma, Inc.
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Bayer
Professional Services and Activities -
Boehringer Ingelheim
Professional Services and Activities (Uncompensated) -
Bristol-Myers Squibb
Professional Services and Activities -
Chinese American Hematology and Oncology Network
Professional Services and Activities -
Clinical Education Alliance, LLC
Professional Services and Activities -
COR2ED GmbH
Professional Services and Activities -
Creative Educational Concepts, Inc.
Professional Services and Activities -
Curio Science LLC
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
ED Medresources Inc
Professional Services and Activities -
Eisai
Professional Services and Activities -
Emory University
Professional Services and Activities -
Fundación Santa Fe de Bogotá
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities (Uncompensated)
-
Guardant Health, Inc.
Professional Services and Activities -
H.C. Wainwright & Co., LLC
Professional Services and Activities -
Hospital Sirio-Libanes
Professional Services and Activities -
Imedex, Inc.
Professional Services and Activities -
Inspirna, Inc.
Equity -
Japan Convention Services, Inc.
Professional Services and Activities -
Merck & Co Inc.
Professional Services and Activities -
MJH Life Sciences
Professional Services and Activities -
Netherlands Cancer Institute
Professional Services and Activities -
PeerView Institute for Medical Education (PVI)
Professional Services and Activities -
PlayToKnow AG
Professional Services and Activities -
Research to Practice
Professional Services and Activities -
Sanofi S.A.
Professional Services and Activities -
Sociedade Brasileira de Oncologia Clínica
Professional Services and Activities -
Talem Health, LLC
Professional Services and Activities -
Total CME
Professional Services and Activities -
Transcenta Holding Limited
Professional Services and Activities -
Webinars.Inc
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].